Bruton tyrosine kinase (BTK)
Bruton agammaglobulinemia tyrosine kinase (BTK) is a non-receptor tyrosine kinase that plays an essential and non-redundant role in B-cell development, maturation, and signaling.
Bruton agammaglobulinemia tyrosine kinase (BTK) is a non-receptor tyrosine kinase that plays an essential and non-redundant role in B-cell development, maturation, and signaling. It is a member of the Tec family of kinases and is encoded by the BTK gene located on the X chromosome. BTK was originally identified as the gene mutated in X-linked agammaglobulinemia (XLA), a primary immunodeficiency characterized by the near-complete absence of circulating B cells and immunoglobulins. In physiological B-cell biology, BTK functions as a pivotal component of the B-cell receptor (BCR) signaling cascade, transmitting activation signals downstream through phospholipase C gamma 2 (PLCG2) and connecting to pathways including the PI3K/Akt signaling pathway, NF-κB, and MAPK. Beyond its canonical role in lymphocytes, BTK is expressed in myeloid lineage cells including neutrophils and macrophages, where it participates in innate immune receptor signaling.
Given its central position in BCR-mediated survival and proliferation signals, BTK has emerged as one of the most validated pharmacological targets in hematological oncology. Small-molecule inhibitors of BTK — spanning covalent, irreversible agents (such as ibrutinib) and next-generation non-covalent inhibitors — have transformed the treatment landscape for B-cell malignancies, particularly chronic lymphocytic leukemia (CLL). More recently, BTK has attracted attention in inflammatory and autoimmune disorders, as well as in exploratory investigations in neurological conditions, reflecting the breadth of its signaling roles across hematopoietic and immune cell types.
Where the papers sit
21 papers from the last 6 months study Bruton tyrosine kinase (BTK) directly · updated from PubMed 15 Nov 2026
Study type 4 clinical trials · 3 observational · 2 human data · 7 preclinical · 5 unclassified
Themes one subject · 1 paradigm shift
Those 21 are all about one subject.
-
BTK-Targeted Therapeutics
BTK therapy is expanding beyond first-generation covalent inhibitors toward noncovalent agents and targeted degraders. Clinical work emphasizes pharmacokinetics, dose modification, real-world outcomes, and efficacy in CLL, DLBCL, PCNSL, and other hematologic malignancies. Preclinical studies are optimizing selectivity, oral exposure, resistance profiles, and platelet-sparing antithrombotic effects. The field is moving toward safer, more durable BTK control while testing activity across broader immune and inflammatory diseases.
BTK is a therapeutic signaling node beyond malignant B cells
The platelet thrombosis model studying NX-2127 and NX-5948 and the Japanese encephalitis virus-infected mouse model studying zinc supplementation both depart from the malignancy-centered assumption that BTK is chiefly a B-cell therapeutic target. In platelets, selective BTK degradation reduced thrombosis without impairing haemostasis, while in macrophages, zinc-mediated inhibition of BTK phosphorylation reduced neuroinflammation and neuronal injury. Together, these findings extend BTK-directed intervention to distinct nonmalignant processes—thrombus formation and virus-induced CNS inflammation—and suggest that cell-specific BTK modulation, rather than generalized inhibition in B-cell disease, is a broader therapeutic strategy 42379226Jun 42340066Jun.
Papers
The 21 papers from the last 6 months that study Bruton tyrosine kinase (BTK) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
BTK-Targeted Therapeutics (21)
- Emerging drug profile: bexobrutideg. Leukemia & lymphoma · 12 Oct 2026 PMID 42860822
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786239
- Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. Cancer · 15 Sept 2026 PMID 42740716
- Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720469
- Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. Clinical and translational science · 2 Sept 2026 PMID 42682178
- Discovery of novel acridine based inhibitors of Bruton's tyrosine kinase (BTK) via pharmacophore modeling and machine learning-driven virtual screening followed by molecular dynamic studies. Journal of computer-aided molecular design · 1 Sept 2026 PMID 42678624
- Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies. European journal of medicinal chemistry · 7 Aug 2026 PMID 42566884
- Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. Advances in therapy · 24 Jul 2026 PMID 42496861
- Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 1 Jul 2026 PMID 42385585
- Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis. Blood advances · 30 Jun 2026 PMID 42379226
- BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules? Blood cancer discovery · 26 Jun 2026 PMID 42360198
- Zinc Inhibits BTK Phosphorylation in Macrophages to Ameliorate Encephalitis in Neurotropic Virus-Infected Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 24 Jun 2026 PMID 42340066
- Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. Oncology and therapy · 22 Jun 2026 PMID 42329588
- A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART). Japanese journal of clinical oncology · 18 Jun 2026 PMID 42315131
- BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability. Journal of hematology & oncology · 18 Jun 2026 PMID 42310786
- Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 15 Jun 2026 PMID 42297099
- PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. Blood advances · 9 Jun 2026 PMID 42263669
- Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. Journal of hematology & oncology · 7 Jun 2026 PMID 42252468
- Common biomarkers of Alzheimer disease and postoperative delirium. Medicine · 30 May 2026 PMID 42216384
- Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. Journal of neuro-oncology · 29 May 2026 PMID 42213292
- QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 May 2026 PMID 42184887
By study type
Clinical trials (4)
- Population pharmacokinetic analysis of pirtobrutinib, a non-covalent BTK inhibitor, in patients with hematological malignancies from the Phase 1/2 BRUIN study. Cancer chemotherapy and pharmacology · 24 Sept 2026 PMID 42786239
- Rocbrutinib, a Highly Selective Fourth-Generation Covalent and Noncovalent BTK Inhibitor, in R/R Non-GCB DLBCL: Efficacy and Safety from a Phase I Study. Advances in therapy · 24 Jul 2026 PMID 42496861
- A multicenter randomized phase II/III trial of salvage treatment for refractory primary central nervous system lymphoma using tirabrutinib: JCOG2314 (ReSTART). Japanese journal of clinical oncology · 18 Jun 2026 PMID 42315131
- Remibrutinib impact on disease control, sleep, and quality of life: Analysis of phase 3 REMIX-1/2. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 15 Jun 2026 PMID 42297099
Observational studies and case reports (3)
- Timing matters: Impact of covalent BTK inhibitor dose modifications on outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia-A 7-year real-world study. Cancer · 15 Sept 2026 PMID 42740716
- Successful treatment of pure red cell aplasia with Orelabrutinib following major ABO-incompatible hematopoietic stem cell transplantation for acute myeloid leukemia: A case report. Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 1 Jul 2026 PMID 42385585
- Candidate MRI biomarkers for CD79B status in primary CNS lymphoma: an exploratory radiogenomic analysis of the UCSF-PCNSL cohort. Journal of neuro-oncology · 29 May 2026 PMID 42213292
Human data, design not indexed (2)
- PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia. Blood advances · 9 Jun 2026 PMID 42263669
- Common biomarkers of Alzheimer disease and postoperative delirium. Medicine · 30 May 2026 PMID 42216384
Preclinical: animal, cell and lab studies (7)
- Discovery of Highly Potent and Selective, Orally Bioavailable BTK-Targeting PROTACs Featuring Novel CRBN-Binding Warheads. Journal of medicinal chemistry · 10 Sept 2026 PMID 42720469
- Physiologically Based Pharmacokinetic Modeling to Predict Human Starting Dose and Pharmacokinetics for Rocbrutinib. Clinical and translational science · 2 Sept 2026 PMID 42682178
- Discovery of novel acridine based inhibitors of Bruton's tyrosine kinase (BTK) via pharmacophore modeling and machine learning-driven virtual screening followed by molecular dynamic studies. Journal of computer-aided molecular design · 1 Sept 2026 PMID 42678624
- Design, synthesis, and biological evaluation of novel 4-aminoquinoline benzoyl hydrazine derivatives as noncovalent BTK inhibitors for hematologic malignancies. European journal of medicinal chemistry · 7 Aug 2026 PMID 42566884
- Zinc Inhibits BTK Phosphorylation in Macrophages to Ameliorate Encephalitis in Neurotropic Virus-Infected Mice. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 24 Jun 2026 PMID 42340066
- BTKi orelabrutinib improved the outcome of newly-diagnosed PCNS-LBCL by alleviating MyD88L265P-induced PIM1 stability. Journal of hematology & oncology · 18 Jun 2026 PMID 42310786
- QbD-based intranasal pH-sensitive Ibrutinib liposomes for glioblastoma management: in vitro, ex vivo, and in vivo pharmacokinetics and brain distribution assessment. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V · 25 May 2026 PMID 42184887
Unclassified: not yet indexed with MeSH (5)
- Emerging drug profile: bexobrutideg. Leukemia & lymphoma · 12 Oct 2026 PMID 42860822
- Selective degradation of platelet BTK by PROTAC NX-5948 provides antithrombotic benefits without affecting haemostasis. Blood advances · 30 Jun 2026 PMID 42379226
- BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules? Blood cancer discovery · 26 Jun 2026 PMID 42360198
- Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. Oncology and therapy · 22 Jun 2026 PMID 42329588
- Novel BTK inhibitors and degraders for relapsed/refractory CLL/SLL: latest updates from ASH 2025 annual meeting. Journal of hematology & oncology · 7 Jun 2026 PMID 42252468
Written from 21 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-26 by GPT. Drafted by language models from published abstracts; not medical advice.